Contact us


Kirov region
in numbers
Foreign investors
in Kirov region
AI "Agency for territorial development of the Kirov region" (AI "ATDKR")
Director General: Savinykh Yuliya Aleksandrovna
Address: 610002, the city of Kirov, 17 Krasnoarmeyskaya street, 2nd floor, suite 201
Tel.: +7 (8332) 70-83-19, +7 (8332) 64-00-28
Fax: +7 (8332) 70-83-19


Kirov Region Development Corporation, OJSC
Director General: Savina Olga Leonidovna
Address: 610042, the city of Kirov, 28 Narodnaya Str.
Tel.: +7 (8332) 411-960



The pharmaceutical company Avva Rus, a subsidiary of Swiss AVVA Pharmaceuticals, intends to build a plant for the production of pharmaceutical substances in Slobodino industrial park (the Kirov Region). The project is estimated at 100 million rubles. "The company plans to implement a project aimed at import substitution of active pharmaceutical substances based on materials of animal and plant origin. The project involves the development of technology and the organization of the substance production,"- Alexei Egorov, Director General of Avva Rus said to Vademecum. The company expects to invest up to 100 million rubles in the project by investing approximately fifty-fifty of borrowed and own funds, explained the Director General.
At the Eastern Economic Forum, Nanolek, a Russian Biopharmaceutical Company, and the South-Korean SK Chemicals signed an agreement on cooperation in the development, research, and production of vaccines, as reported by the Nanolek’s press service.
Italian company Pirelli will invest circa RUB 1 bn into the development of Kirov Tire Plant by late 2016, according to the Kirov Region Government's Press service.
Listrade LLC plans to inaugurate its ice-cream stick production in Kirov Region with a total capacity of 300 tpm.
The Russian pharmaceutical producer Pharmstandard, National Immunobiological Company (Nacimbio, part of Rostekh) and the Italian pharmaceutical company Kedrion Biopharma have become founders of Kirov Plasma JSC, located on the territory of the unfinished Kirov plant for the production of blood products Rosplazma.
Teva, an Israeli pharma producer, localizes its production at the facilities of Russian Nanolek, a Rosnano portfolio company. Representatives of both companies informed Vedomosti that the companies have executed their agreement to the effect on 27 September.

Subscribe to Newsletters


Select a region